Company Description
Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States.
Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats.
The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.
In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies.
Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.
| Country | Canada |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | James A. Joyce Ph.D. |
Contact Details
Address: 9190 W Olympic Blvd # 263 Beverly Hills, California 90212 United States | |
| Phone | 619-368-2000 |
| Website | sigyntherapeutics.com |
Stock Details
| Ticker Symbol | SIGY |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001642159 |
| CUSIP Number | 82674U106 |
| ISIN Number | US82674U1060 |
| Employer ID | 47-2573116 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| James A. Joyce Ph.D. | Co-founder, Chairman and Chief Executive Officer Inventor |
| Craig P. Roberts | Co-founder, Chief Technology Officer and Director |
| Gerald DeCiccio C.P.A., M.B.A. | Chief Financial Officer |
| Charlene R. Owen | Director of Operations |
| Dr. Annette Marleau Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | 8-K | Current Report |
| Apr 10, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Feb 20, 2024 | 10-K | Annual Report |
| Feb 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 31, 2024 | 8-K | Current Report |
| Jan 30, 2024 | 8-K | Current Report |
| Jan 11, 2024 | 8-K | Current Report |
| Jan 8, 2024 | 8-K | Current Report |
| Dec 12, 2023 | 8-K | Current Report |
| Nov 14, 2023 | 10-Q | Quarterly Report |